JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/55/0.1/17.01.25 | Market Closed - Börse Stuttgart 05:20:08 2024-07-05 am EDT | ||
| 0.028 EUR | +3.70% |
|
| Current month | -24.32% | ||
| 1 month | -20.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 0.028 | +3.70% |
| 24-07-04 | 0.027 | 0.00% |
| 24-07-03 | 0.027 | -18.18% |
| 24-07-02 | 0.033 | -23.26% |
| 24-07-01 | 0.043 | +16.22% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 05:20 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | J.P. Morgan |
| WKN | JB5SNC |
| ISIN | DE000JB5SNC7 |
| Date issued | 2023-11-01 |
| Strike | 55 $ |
| Maturity | 2025-01-17 (195 Days) |
| Parity | 10 : 1 |
| Emission price | 0.42 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.47 € |
|---|---|
| Lowest since issue | 0.027 € |
| Spread | 0.01 € |
| Spread % | 27.03% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
39.66
USD
Average target price
53.19
USD
Spread / Average Target
+34.13%
- Stock Market
- Warrants
- Warrant
